Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Debt (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Debt for 4 consecutive years, with $209.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 3.81% to $209.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $209.1 million through Dec 2025, up 3.81% year-over-year, with the annual reading at $209.1 million for FY2025, 3.81% up from the prior year.
  • Non-Current Debt for Q4 2025 was $209.1 million at Phathom Pharmaceuticals, up from $207.1 million in the prior quarter.
  • The five-year high for Non-Current Debt was $209.1 million in Q4 2025, with the low at $91.0 million in Q1 2022.
  • Average Non-Current Debt over 4 years is $145.6 million, with a median of $143.4 million recorded in 2023.
  • The sharpest move saw Non-Current Debt surged 78.34% in 2024, then increased 3.81% in 2025.
  • Over 4 years, Non-Current Debt stood at $95.3 million in 2022, then surged by 44.69% to $137.8 million in 2023, then skyrocketed by 46.12% to $201.4 million in 2024, then grew by 3.81% to $209.1 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $209.1 million, $207.1 million, and $205.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.